Cancer Archives

News and Trends 18 Aug 2015

Not only Genes matter, Cellular Origin determines the Cancer Type

Cancer occurs in uncountable forms, and we are far away from understanding all the mechanisms that lead to its variety. For example, did you know that not only the mutated gene is responsible for the emerging of a certain type of cancer but also its cellular origin? That’s what researcher from Belgium and Australia just […]

August 18, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Aug 2015

Roche abandons Wilex to Make Way for Immuno-Oncology

Roche just dropped a first-generation antibody-based treatment preventing cancer cells from proliferating. Interestingly enough, the partner of the collaboration, Wilex’ subsidiary Heidelberg Pharma, stated the research “progressed well, on schedule, and in a mutually satisfactory manner”. What happened? Heidelberg Pharma is a German company that discovers new drugs using its platform technology for antibody drug […]

August 13, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

Roche and Clovis combine drugs to fight lung cancer, the most common cancer worldwide

Roche‘s subsidiary Genentech joined forces with NASDAQ-listed Clovis Oncology to evaluate a novel combination therapy for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC). Its anti PD-L1 cancer immunotherapy and Clovis’ rociletinib will enter Phase Ib/II in 2015. With 1.35 million new cases annually, lung cancer is the most common cancer worldwide. In […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Aug 2015

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

The massive expansion of AstraZeneca’s pipeline continues, as its biological subsidiary, MedImmune buys Inovio Pharmaceuticals‘ clinical-stage cancer vaccine that targets cancer caused by the human papillomavirus (HPV). MedImmune, which makes up nearly 50% of AstraZeneca’s pipeline, may spend over $720M (€653M) to bolster its cancer-associated portfolio. HPV is the most commonly sexually transmitted virus and […]

August 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

Evotec had to announce a setback recently when its Alzheimer’s treatment in collaboration with Roche failed in Phase IIb. However, another strong partner on its side, Sanofi, never lost trust in the German biotech’s value. In the last three days, the French giant entered into two new projects with Evotec, which target diabetes and immuno-oncology. […]

August 10, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire exclusive global rights on the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating […]

August 10, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 30 Jul 2015

NASDAQ-listed Sprint Bioscience sells early-stage Cancer Treatment to Bayer

Just as Boehringer Ingelheim, Bayer HealthCare expands its cancer portfolio this week. The German company is inclined to shell out €190M for a drug that interacts with the peculiar metabolism of cancer cells. Its developer, Sprint Bioscience AB, is a Swedish company founded in 2009, from former members of AstraZeneca, Biovitrum, and Pharmacia. Sprint Bioscience is a […]

July 30, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 30 Jul 2015

Boehringer Ingelheim signs €661M deal for New Lung Cancer Treatment

Boehringer Ingelheim puts a new pillar in its oncology pipeline. The German giant acquired a Phase II compound for the treatment of lung cancer from the Korean pharma company Hamni. Non-small cell lung cancer makes up about 90% of all lung cancers. A targeted therapy includes the inhibition of the epidermal growth factor receptor (EGFR), […]

July 30, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer, announced today that data from its Phase I/II study in patients with multiple myeloma has been published in Nature Medicine. This is the first report on TCR engineered T-cell therapy that shows durable persistence in patients! After its successful intoduction on […]

July 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 21 Jul 2015

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

A new partnering deal in the trendy field of immune-oncology. Boston-based Agenus signed a €40M deal with Italian Biotech Diatheva to get antibodies, which are targeting a glycoprotein expressed on T cell and NK cell lymphocytes to boost the immune system of patients to fight major cancer. The Boston (Lexington)-based company Agenus went on the NASDAQ […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 21 Jul 2015

BMS steps into the European Market with its new Lung Cancer Treatment

It’s the first major treatment for metastatic squamous non-small cell lung cancer (NSCLC) to have been approved in over a decade in Europe: Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Nivolumab was granted with market authorization by the European Commission. The drug is the first to improve overall survival in previously-treated metastatic NSCLC. Just one month […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Jul 2015

Theravectys’ HIV Cure on the Road to Success

Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic vaccine using lentivirus could be the first cure available for the 35 million people currently suffering from this worldwide epidemic. Paris-based Theravectys presented detailed results from its phase I/II study at the 2015 Towards an HIV Cure Symposium in Vancouver, Canada. The trial currently enrolled 38 HIV-positive patients […]

July 20, 2015 - 3 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Not only Genes matter, Cellular Origin determines the Cancer Type

Roche abandons Wilex to Make Way for Immuno-Oncology

Roche and Clovis combine drugs to fight lung cancer, the most common cancer worldwide

AstraZeneca’s Oncology Expansion Continues: MedImmune grabs Inovio’s Cancer Vaccine

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

NASDAQ-listed Sprint Bioscience sells early-stage Cancer Treatment to Bayer

Boehringer Ingelheim signs €661M deal for New Lung Cancer Treatment

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

NASDAQ-listed Biotech from Boston shops cancer-treating antibodies in Italy

BMS steps into the European Market with its new Lung Cancer Treatment

Theravectys’ HIV Cure on the Road to Success

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!